Recombinant Mouse Mesothelin (aa 36-288) His-tag Protein, CF

2 μg/lane of Recombinant Mouse Mesothelin (aa 36-288) His-tag Protein (Catalog # 10516-MS) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 29-45 kDa.

• Reactivity: Mu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Mouse Mesothelin (aa 36-288) His-tag Protein, CF Summary

• Additional Information: N-Terminal/MPF
• Details of Functionality: Bioassay data are not available.
• Source: Mouse myeloma cell line, NS0-derived mouse Mesothelin protein
  Gln36-Leu288, with a C-terminal 6-His tag
• Accession #: Q61468.1
• N-terminal Sequence: Gln36 inferred from enzymatic pyroglutamate treatment revealing Thr37
• Structure / Form: Monomer
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 29 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 29-45 kDa, under reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 500 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Mouse Mesothelin (aa 36-288) His-tag Protein, CF

• CAK1 antigen
• CAK1
• megakaryocyte potentiating factor
• Mesothelin
• MPF
• MPFSMRP
• MSLN
• Pre-pro-megakaryocyte-potentiating factor
• SMR
• soluble MPF mesothelin related protein

Background

Mesothelin N-terminal, commonly known as Megakaryocyte Potentiating Factor (MPF), is a 31 kDa soluble protein that was originally identified in an PHC-Y5 culture system where it exhibited megakaryocyte potentiating activity (1). MPF is closely related to mesothelin (MSLN), a 40 kDa glycosylphosphatidyl inositol (GPI)-linked protein that is highly overexpressed in various types of cancer, such as mesothelioma, ovarian and pancreatic cancers (2). Both MPF and MSLN originate from a common 71 kDa precursor protein that harbors a furin cleavage site between amino acid residues 288-293. The 31 kDa soluble N-terminal MPF fragment is secreted into blood and the C-terminal 40 kDa fragment remains membrane-bound and classified as mature mesothelin (3). Mouse MPF is composed of residues 36-288 from the precursor protein and contains one N-linked glycosylation site (N93) and one phosphorylated serine (S202). Mouse MPF shares 56% and 84% sequence identity with human and rat MPF, respectively. It is expressed mainly in the heart and lungs (4) and can be upregulated in the presence of Wnt-1 (5). MSLN was shown to be capable of binding to cancer antigen 125/mucin16 (CA125/MUC16). Apart from its role as a megakaryocyte potentiating cytokine, MPF may have the potential to serve as a biomarker for detection and monitoring of malignant mesothelioma and related cancers (6).

1. Yamaguchi, N. et al. (1994) J. Biol. Chem. 260: 22:805.
2. Hassan R. et al. (2004) Clin. Cancer Res. 10:3937.
3. Shiomi, K. et al. (2006) Cancer. Sci. 97:928.
4. Bera T.K. Pastan I. (2000) Mol. Cell. Biol. 20:2902.
5. Prieve M.G. Moon R.T. (2003) BMC Dev Biol. 3:2.
6. Raiko, I. et al. (2017) Biochem. Biophy. Res. Com. 486:526.

Bioinformatics

• Uniprot:
  • Q61468.1()